How is gastric amyloidosis diagnosed and managed?

Gastric Amyloidosis: Diagnosis and Management

Gastric amyloidosis requires tissue biopsy with Congo red staining demonstrating apple-green birefringence under polarized light for definitive diagnosis, followed by amyloid protein typing to guide systemic treatment targeting the underlying plasma cell dyscrasia 1, 2.

Diagnostic Approach

Clinical Presentation

Gastric amyloidosis presents with nonspecific symptoms that correlate poorly with the degree of tissue deposition 2. Key manifestations include:

• Bleeding-related symptoms (most common at 66.7% of cases) 3
• Refractory nausea and vomiting (33.3% of cases) 3
• Chronic dyspepsia unresponsive to proton pump inhibitors 4
• Weight loss and abdominal pain 5
• Obstruction in severe cases 3

Critical pitfall: Symptoms often mimic common GI disorders like GERD or peptic ulcer disease, leading to delayed diagnosis 2, 4. Maintain high suspicion in patients with persistent symptoms despite standard therapy.

Endoscopic Findings

The antrum is the most frequently involved site (61.5%) 3, though any gastric region can be affected. Endoscopic appearances include:

• Nodules, polyps, masses, or elevated lesions (57.1% of cases) 3
• Mucosal erosions and nodular changes 4
• Polypoid elevations that may fluctuate with disease activity 3

Important caveat: Endoscopic findings are nonspecific and can resemble neoplastic lesions, fundic gland polyps, or inflammatory changes 3, 4.

Definitive Diagnosis

Duodenal biopsy is the most reliable diagnostic site for GI amyloidosis 2, though gastric biopsies are diagnostic when positive. The diagnostic algorithm:

1. Obtain multiple adequate biopsies with deeper sampling when initial biopsies are negative but suspicion remains high 3
2. Congo red staining is mandatory - routine H&E may miss the diagnosis 3
3. Confirm apple-green birefringence under polarized light 6, 4, 5
4. Amyloid protein typing (mass spectrometry preferred) to distinguish AL from AA or ATTR subtypes 5

Systemic Evaluation

Once gastric amyloidosis is confirmed, assess for systemic involvement:

• Serum and urine free light chains (elevated in AL amyloidosis) 5
• Serum protein electrophoresis with immunofixation (monoclonal protein in AL) 5
• Cardiac biomarkers (troponin, NT-proBNP) - cardiac involvement drives prognosis and mortality 1
• Echocardiography with strain imaging 5
• Bone marrow biopsy to identify plasma cell clone 1
• Hepatic assessment - Fibroscan shows promise for detecting hepatic involvement 2

Key diagnostic sequence: In 56% of cases, MM or plasma cell dyscrasia is diagnosed after GI amyloid is identified, while 44% develop gastric involvement with known MM 3. Always evaluate for systemic disease regardless of presentation sequence.

Management Strategy

Treatment of Underlying Disease (AL Amyloidosis)

The hallmark of management is early treatment before irreversible organ damage occurs 1. Treatment is transplant-eligibility driven:

ASCT-Eligible Patients (~20%)

• Autologous stem cell transplantation (ASCT) remains standard of care 1
• May include bortezomib-based induction therapy 1

ASCT-Ineligible Patients (majority)

• Bortezomib-based regimens are central to upfront treatment 1
• Daratumumab (anti-CD38 antibody) is the emerging standard of care added to bortezomib regimens 1, 7
• Goal: achieve deep, durable hematologic responses with close monitoring for early relapse detection 1

Treatment principle: Target the plasma cell clone to halt amyloidogenic light chain production and prevent progressive organ damage 1.

Gastric-Specific Management

Supportive care and nutritional intervention are essential across all subtypes 2:

• Symptomatic management for nausea, vomiting, bleeding 6
• Nutritional support - critical given frequent weight loss and malabsorption 2, 5
• Proton pump inhibitors for erosive disease, though underlying amyloid requires systemic treatment 4
• Observation or localized surgical excision only for truly localized disease without systemic involvement 6

Important observation: Gastric manifestations may track plasma cell clonal activity, with polypoid lesions decreasing after effective anti-myeloma therapy and recurring with disease progression 3. This supports the primacy of systemic treatment over local interventions.

Monitoring

• Serial endoscopy can document response to systemic therapy 3
• Close monitoring of hematologic response (free light chains, monoclonal protein) 1
• Cardiac surveillance given that cardiac involvement is the main driver of mortality 1
• Early detection of relapse/refractory disease is critical 1

Prognosis Considerations

Cardiac involvement is the main driver of prognosis and mortality 1. More than 69% of patients have multiple organ involvement at diagnosis 1, emphasizing the need for comprehensive systemic evaluation even when gastric symptoms predominate.

Quality of life impact: Early diagnosis and treatment significantly improve outcomes, as delayed diagnosis often occurs after irreversible organ damage 1, 2.